Isolation and Characterization of a Monobody with a Fibronectin Domain III Scaffold That Specifically Binds EphA2

Antibody-Dependent Cell-Mediated Cytotoxicity Effector-Enhanced EphA2 Agonist Monoclonal Antibody Demonstrates Potent Activity against Human Tumors

(2015) Elizabeth M. Bruckheimer et al.   NEOPLASIA

Enhancement in Specific CD8+ T Cell Recognition of EphA2+ Tumors In Vitro and In Vivo after Treatment with Ligand Agonists

(2014) A. K. Wesa et al.   JOURNAL OF IMMUNOLOGY

99mTc-labeled SWL specific peptide for targeting EphA2 receptor

(2014) Yu Liu et al.   NUCLEAR MEDICINE AND BIOLOGY

Engineering of Bacteria for the Visualization of Targeted Delivery of a Cytolytic Anticancer Agent

(2013) Sheng-Nan Jiang et al.   MOLECULAR THERAPY

Use of64Cu-labeled Fibronectin Domain with EGFR-Overexpressing Tumor Xenograft: Molecular Imaging

(2012) Benjamin J. Hackel et al.   RADIOLOGY

High Affinity, Developability and Functional Size: The Holy Grail of Combinatorial Antibody Library Generation

(2011) Dirk Ponsel et al.   MOLECULES

Structure−Activity Relationship Analysis of Peptides Targeting the EphA2 Receptor

(2010) Sayantan Mitra et al.   BIOCHEMISTRY

Chemosensitization of cancer cells by siRNA using targeted nanogel delivery

(2010) Erin B Dickerson et al.   BMC CANCER

EphA2Mutation in Lung Squamous Cell Carcinoma Promotes Increased Cell Survival, Cell Invasion, Focal Adhesions, and Mammalian Target of Rapamycin Activation

(2010) Leonardo Faoro et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Stability and CDR Composition Biases Enrich Binder Functionality Landscapes

(2010) Benjamin J. Hackel et al.   JOURNAL OF MOLECULAR BIOLOGY

The full amino acid repertoire is superior to serine/tyrosine for selection of high affinity immunoglobulin G binders from the fibronectin scaffold

(2010) B. J. Hackel et al.   PROTEIN ENGINEERING DESIGN & SELECTION

Adnectins: engineered target-binding protein therapeutics

(2010) D. Lipovsek   PROTEIN ENGINEERING DESIGN & SELECTION

Eph Receptors and Ephrin Ligands: Important Players in Angiogenesis and Tumor Angiogenesis

(2010) Birgit Mosch et al.   Journal of Oncology

Kinase-Dependent and -Independent Roles of EphA2 in the Regulation of Prostate Cancer Invasion and Metastasis

(2009) Maria Letizia Taddei et al.   AMERICAN JOURNAL OF PATHOLOGY

Peptide-Functionalized Nanogels for Targeted siRNA Delivery

(2009) William H. Blackburn et al.   BIOCONJUGATE CHEMISTRY

EphA2 Reexpression Prompts Invasion of Melanoma Cells Shifting from Mesenchymal to Amoeboid-like Motility Style

(2009) M. Parri et al.   CANCER RESEARCH

Engineered protein scaffolds as next-generation antibody therapeutics

(2009) Michaela Gebauer et al.   CURRENT OPINION IN CHEMICAL BIOLOGY

FN3: a new protein scaffold reaches the clinic

(2009) Laird Bloom et al.   DRUG DISCOVERY TODAY

EphA2 Immunoconjugate as Molecularly Targeted Chemotherapy for Ovarian Carcinoma

(2009) Jeong-Won Lee et al.   JNCI-Journal of the National Cancer Institute

Selective removal of ovarian cancer cells from human ascites fluid using magnetic nanoparticles

(2009) Kenneth E. Scarberry et al.   Nanomedicine-Nanotechnology Biology and Medicine

A Human Antibody-Drug Conjugate Targeting EphA2 Inhibits Tumor Growth In vivo

(2008) D. Jackson et al.   CANCER RESEARCH

Picomolar Affinity Fibronectin Domains Engineered Utilizing Loop Length Diversity, Recursive Mutagenesis, and Loop Shuffling

(2008) Benjamin J. Hackel et al.   JOURNAL OF MOLECULAR BIOLOGY

Magnetic Nanoparticle−Peptide Conjugates for in Vitro and in Vivo Targeting and Extraction of Cancer Cells

(2008) Kenneth E. Scarberry et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY